Spark Therapeutics Announces Participation in Conferences in July
- Cantor Fitzgerald’s 2nd Annual Healthcare Conference at Le Park Meridien in
New York City Stephen Webster, Spark’s chief financial officer, will present on Wednesday July 13, 2016at 10:45 am (ET)and also will participate in a gene therapy panel at 12:15 pm (ET)
World Federation of Hemophilia(WFH) 2016 World Congressin Orlando, FL
Lindsey George, a hematologist at the Children's Hospitalof Philadelphiaand the lead clinical investigator in the Phase 1/2 clinical trial of SPK-9001 for the treatment of hemophilia B, will present a moderated poster presentation on Monday July 25, 2016at 4:00 pm (ET)
- Dr. George also will present at a late-breaking abstract session on gene therapy on
Wednesday July 27, 2016at 2:15 pm (ET).
About Hemophilia B
Hemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot as a result of a deficiency in one of several blood clotting factors, and occurs almost exclusively in males. People with hemophilia face specific risks as they are not able to form blood clots efficiently and are at risk for excessive and recurrent bleeding from modest injuries, which have the potential to be life threatening. People with severe hemophilia often bleed spontaneously into their muscles or joints. The incidence of hemophilia B is one in 25,000 male births. People with hemophilia B have a deficiency in clotting factor IX, a specific protein in the blood. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Current standard of care requires recurrent intravenous infusions of either plasma-derived or recombinant factor IX to control and prevent bleeding episodes. There exists a significant need for novel therapeutics to treat people living with hemophilia.
About the SPK-FIX Program
Spark's proprietary technology platform for selecting, designing, manufacturing and formulating highly optimized gene therapies was applied to developing compounds in the SPK-FIX program. The SPK-FIX program leverages a long track record of hemophilia gene therapy research and clinical development conducted by Spark and its founding scientific team over nearly three decades. SPK-9001 is a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized high-activity human factor IX variant enabling endogenous production of factor IX. SPK-9001 is being developed under a collaboration with Pfizer. Spark and Pfizer entered into a collaboration in 2014 for the SPK-FIX program, including SPK-9001, under which Spark is responsible for conducting all Phase 1/2 studies for any product candidates, while Pfizer will assume responsibility for pivotal studies, any regulatory activities and potential global commercialization of any products that may result from the collaboration.
Contacts Corporate Contacts:
Stephen W. WebsterChief Financial Officer Spark Therapeutics, Inc. Daniel FagaChief Business Officer Spark Therapeutics, Inc.(855) SPARKTX (1-855-772-7589) Media Contact: Ten Bridge Communications Dan Quinn(781) 475-7974 email@example.com